Author: Leah Kosyakovsky

Transcatheter Mitral-valve Repair Lowers Hospitalization or CV Death vs Medical Therapy Alone in HF with Moderate to Severe MR: RESHAPE-HF2 Trial
ESC 2024, News

Transcatheter Mitral-valve Repair Lowers Hospitalization or CV Death vs Medical Therapy Alone in HF with Moderate to Severe MR: RESHAPE-HF2 Trial

Key Points: The Mitral Transcatheter Edge-to-Edge Repair (M-TEER) procedure with the MitraClip device has shown in the previous COAPT trial to reduce heart failure... Read more.
Pooled Analysis Showed Semaglutide Reduced Combined CV death or Worsening HF and Worsening HF alone but No Significant Effect on CV Death
ESC 2024, News

Pooled Analysis Showed Semaglutide Reduced Combined CV death or Worsening HF and Worsening HF alone but No Significant Effect on CV Death

Key Points: Heart failure with mildly reduced or preserved ejection fraction (hereafter referred to as HFpEF) is the most common type of heart failure and is associated... Read more.
Transcatheter Edge-To-Edge Repair Is Non-Inferior To Surgery In Patients With Secondary Mitral Regurgitation: MATTERHORN Trial
ESC 2024, News

Transcatheter Edge-To-Edge Repair Is Non-Inferior To Surgery In Patients With Secondary Mitral Regurgitation: MATTERHORN Trial

Key Points: The MATTERHORN trial found that the transcatheter edge-to-edge repair (TEER) procedure was non-inferior to surgical mitral valve repair in reducing functional... Read more.
T-TEER Significantly Reduced the Severity of Secondary Tricuspid Regurgitation and Improved Quality of Life. TRI-FR Trial
ESC 2024, News

T-TEER Significantly Reduced the Severity of Secondary Tricuspid Regurgitation and Improved Quality of Life. TRI-FR Trial

Key Points: The TRI.FR trial found that tricuspid transcatheter edge-to-edge repair (T-TEER) together with optimal medical therapy significantly improved the clinical... Read more.
Consistent Renal Benefits of Semaglutide in CKD and T2DM Patients With or Without SGLT2 Inhibitors Use. FLOW Trial
ADA 2024, Diabetes mellitus

Consistent Renal Benefits of Semaglutide in CKD and T2DM Patients With or Without SGLT2 Inhibitors Use. FLOW Trial

The FLOW trial showed that among patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), once-weekly subcutaneous semaglutide was superior to placebo... Read more.
Tirzepatide Reduced Apnea-hypopnea Index and Weight in Obese Patients with Moderate Sleep Apnea: SURMOUNT-OSA Trials
ADA 2024

Tirzepatide Reduced Apnea-hypopnea Index and Weight in Obese Patients with Moderate Sleep Apnea: SURMOUNT-OSA Trials

Obstructive sleep apnea is associated with cardiovascular complications and is seen more commonly in individuals with excess adiposity. The SURMOUNT OSA phase 3... Read more.